Goldline Pharmaceutical came to market through an SME IPO that opened on 12 May 2026 and closed on 14 May 2026, and the shares listed on 19 May 2026 on BSE SME. The price band was ₹41 to ₹43 per share and one lot was 3000 shares, so the minimum application was ₹1,29,000. The issue size was ₹11.61 crore. The whole issue was fresh shares, so the money raised went to the company.
Bigshare Services Pvt.Ltd was the registrar to the issue, and Cumulative Capital Pvt.Ltd was the lead manager.
As of 14 May 2026.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Goldline Pharmaceuticals has engaged itself in marketing pharmaceutical products branded as 'Goldline'. The product line of Goldline can be categorized into five groups: Goldline Pharma: It includes a range of 42 products for specialties including Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. Goldline Cardinal: It consists of a range of 54 products for the Specialty division in medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians. Goldline Aayushman:
It consists of a range of 18 products for the Specialty division in medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners. Goldline InLife: It includes a range of 22 products for the Specialty division in medical fields such as Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. Goldline Wellness: It consists of a range of 10 products for Supportive care for patients undergoing chemotherapy for their illness.
As the company does not manufacture any products, it collaborates with third parties which manufacture medicines according to market analysis and product specifications of the company.
The firm does not produce any products but rather works with third-party producers who manufacture their products as per the firm's market research and product descriptions, thus ensuring quality and regulatory compliance.Their products are all marketed and sold using the Goldline brand name by our distribution partners who distribute the products to retailers and wholesalers.
Currently, the firm uses 15 producers and 7 distribution firms for selling its products, and it also helps hospitals and healthcare institutions in procurement and supplies. The firm sells products in the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
As described in the offer document.
| Metric | 31-Dec-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Amol Laxmikant Mujumdar, Swapan Premprakash Khandelwal.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Goldline Pharmaceutical IPO was a ₹11.61 crore book-built issue, made up entirely of a fresh issue. It was priced at ₹41–₹43 per share with a lot size of 3,000 shares; the minimum retail application was 6,000 shares (₹2,58,000). The IPO was open from May 12 to May 14, 2026 and was subscribed 840.81x. Shares listed on BSE SME on May 19, 2026 at ₹59.75, a 39.0% premium to the issue price of ₹43. Bigshare Services Pvt. Ltd. is the registrar.
Cumulative Capital Pvt. Ltd. is the book running lead manager.
The price band of Goldline Pharmaceutical IPO is ₹41 to ₹43 per share.
The lot size of Goldline Pharmaceutical IPO is 3000 shares.
The minimum investment for Goldline Pharmaceutical IPO is approximately ₹2,58,000 based on the upper price band.
The allotment date of Goldline Pharmaceutical IPO is May 15, 2026.
Goldline Pharmaceutical IPO's final recorded GMP before listing was ₹14 per share (a 33% premium over the ₹43 upper price band). The shares listed at ₹59.75. GMP is unofficial and does not forecast or guarantee the actual listing price.
You can check Goldline Pharmaceutical IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Goldline Pharmaceutical IPO allotment status on Rupix for quick and easy access.
₹41 to ₹43 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 3000 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,29,000. After listing, SME shares also trade in lots rather than one share at a time.
₹1,29,000, for one lot of 3000 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 12 May 2026 and closed on 14 May 2026.
The basis of allotment was published on 15 May 2026 by Bigshare Services Pvt.Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 19 May 2026 on BSE SME.
The issue size was ₹11.61 crore. The fresh issue was 27,00,000 shares (aggregating up to ₹11.61 crore).